## TG-Interacting Factor 1 expression quantitatively impacts survival in acute myeloid

2 leukemia

1

3

7

13

18

- 4 Ling Yan<sup>1,\dirthtarrow</sup>, Julie A. Means-Powell<sup>2,\dirthtarrow</sup>, Danko Martincic<sup>2</sup>, Vladimir D. Kravtsov<sup>2</sup>, Yu Shyr<sup>3,4,7</sup>,
- 5 John P. Greer<sup>2</sup>, Utpal P. Davé<sup>2,7,8</sup>, Mark J. Koury<sup>2,7,8</sup>, David Wotton<sup>9</sup>, Rizwan Hamid<sup>1,6,7,\*</sup>, and
- 6 Stephen J. Brandt<sup>2,5,6,7,8</sup>\*
- 8 Departments of Pediatrics<sup>1</sup>, Medicine<sup>2</sup>, Biostatistics<sup>3</sup>, Biomedical Informatics<sup>4</sup>, Cell and
- 9 Developmental Biology<sup>5</sup>, Cancer Biology<sup>6</sup>, Vanderbilt-Ingram Cancer Center<sup>7</sup> of Vanderbilt
- 10 University Medical Center, Nashville, TN, 37232, and VA Tennessee Valley Healthcare
- 11 System<sup>8</sup>, Nashville, TN, 37212; Department of Biochemistry and Molecular Genetics, University
- of Virginia School of Medicine, Charlottesville, VA<sup>9</sup>.
- Mailing address: Rizwan Hamid, Division Medical Genetics and Genomic Medicine,
- Department of Pediatrics, Room DD2205 MCN, Vanderbilt University Medical Center,
- 16 Nashville, TN 37232. Phone: 615-936-1809. Fax: 615-936-3853. E-mail:
- 17 <u>rizwan.hamid@vumc.org</u>

**Abstract** 

Applying transcriptional profiling analysis to myeloblasts from 59 adult patients with acute myeloid leukemia (AML) treated at our institution, we found that expression of the three-amino acid loop extension (TALE) homeobox gene *TG-Interacting Factor 1* (*TGIF1*) correlated with overall and relapse-free survival, which was then confirmed in two other cohorts of patients.

Moreover, *TGIF1* expression correlated with survival for all cytogenetic risk groups and was an independent prognostic factor in multivariate analysis. To elucidate the mechanism, we used *Tgif1* knockout mice in which acute or chronic myeloid leukemia was induced through retroviral transfer of the *MLL-AF9* or *BCR-ABL* fusion genes into bone marrow cells. Loss of *Tgif1* accelerated disease progression, shortened survival, attenuated the response to chemotherapy, and doubled the frequency of leukemia-initiating cells. RNA-based sequencing analysis showed that genes associated with transforming growth factor-β (TGF-β) and retinoic acid signaling pathways were differentially affected in *Tgif1*-/- compared to *Tgif1*-/- leukemia cells.

#### Introduction

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

Acute myeloid leukemia (AML) is an aggressive and heterogeneous disease that most commonly occurs in the elderly. Although a majority of patients achieve a complete remission (CR) with induction and consolidation chemotherapy, most will eventually relapse, with overall survival (OS) ranging from 10-35% 1,2. As a result, clinical indicators have been sought that could inform post-remission therapy and improve long-term survival <sup>3,4</sup>. Established predictors of outcome include patient age, white blood cell (WBC) count, antecedent myelodysplastic syndrome, and, of greatest significance, the presence of specific chromosomal rearrangements in leukemia cells <sup>5</sup>. Patients with t(15;17), t(8;21), or inv(16) enjoy the longest overall survival (OS), while t(6;9), 11q23, monosomy of chromosomes 5 or 7, and complex karyotypes confer the worst prognoses, with 80% of these individuals ultimately relapsing <sup>6</sup>. The largest group of patients, however, has either a normal karyotype or specific cytogenetic abnormalities that put them at some intermediate risk of relapse and death <sup>7,8</sup>. Patients in the favorable risk group can be successfully treated with intensive chemotherapy only 8, while those in the high-risk group require an allogeneic hematopoietic stem cell transplant (SCT) in remission for long term survival 9. In contrast, the optimum therapy for intermediaterisk patients is unclear. Given the substantial number of individuals in whom a cytogenetic marker is not present or prognostic, additional, especially molecular, predictors of survival have been sought. One of the most extensively characterized molecular abnormalities is an internal tandem duplication (ITD) of the gene for Fms-Related Tyrosine Kinase 3 (FLT3). While found to impact survival in some analyses 10,11, no difference in that of FLT3 ITD-positive and ITDnegative patients was detected in other studies <sup>12,13</sup> as assessed independently of other mutations, in particular those in the *nucleophosmin* (NPMI) gene. More than one ITD <sup>10</sup>, a high ratio of

mutant to wild-type DNA <sup>12, 13</sup>, and loss of the wild-type allele have been more clearly linked to a poor prognosis. Rearrangement and/or altered expression of other genes altered or not have been found to have prognostic value. Increased expression of the oncogene Ecotopic Viral Integration Site 1 (EVII), for example, was associated with inferior survival in adults with de novo AML 14, while reduced expression of the *Deleted in Colorectal Carcinoma* (DCC) gene was an independent prognostic factor for CR and OS 15. Further, overexpression of the Brain And Acute Leukemia, Cytoplasmic (BAALC) gene had an adverse impact on overall survival (OS) and disease free survival (DFS) in a study of younger adults with cytogenetically normal de novo AML 16, and mutation of the gene encoding the myeloid transcription factor C/EBPα (CEBPA) was associated with a better outcome in patients in the intermediate-risk group 17, 18. Increasingly, expression profiling and deep sequencing approaches have been used to distinguish groups of patients differing in biology as well as survival. Analyzing global gene expression profiles from a cohort of patients treated at our institution, we discovered that the abundance of mRNA for the three-amino acid loop extension (TALE) superclass homeobox gene *TG-Interacting Factor1* (*TGIF1*) <sup>19-22</sup> correlated very significantly with measures of survival. Analysis of its actions in Tgifl knockout mice in which acute or chronic myeloid leukemia was induced revealed that Tgif1 abundance affected the number and/or function of leukemia-initiating cells (LICs), also referred to as leukemia stem cells (LSCs). This observation has important prognostic and therapeutic implications.

#### **Results**

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

TGIF1 expression is associated with clinical outcomes in AML. To identify new predictors of outcome, we carried out microarray analysis of leukemia cellular RNA from 59 of the 60 adult patients with AML treated at our institution (Supplemental Table S1). Modified Cox regression analysis was then used to identify genes whose expression correlated with OS. A group of 38 genes were predictive with a P < 0.001 and of 5 genes with a P < 0.0001, while the expression of a single gene, TGIF1, correlated with OS with the greatest significance (P < 0.00001). Kaplan-Meier analysis of patient survival in this cohort showed that only 8% (3/39) of individuals whose leukemia cells contained lower levels of TGIF1 mRNA than the reference remained alive at last follow-up (median survival = 181 days, confidence interval (CI) = 112-249 days), while 60% (12/20) of patients who expressed TGIF1 at higher levels survived. Since more than half of patients with higher TGIF1 expression were living at last analysis, median survival could not be determined. Log-rank analysis revealed that individuals with lower TGIF1 expression had significantly shorter OS (Figure 1A) and relapse-free survival (RFS) (Figure 1B) than the group with higher expression. Although a commercial RNA preparation was used to stratify patients into lower and higher expressers, the best cut-point in TGIF1 expression for discriminating survival determined by receiver operating characteristic analysis was close to that in the commercial reference (data not shown). When patients were segregated by TGIF1 expression in quartiles, a concentration-dependent relationship between TGIF1 expression and outcome was suggested (Figure 2A). Finally, TGIF1 expression correlated with OS with even greater statistical significance when analyzed as a continuous variable (P < 0.0001). TGIF1 expression correlated with survival for risk groups defined by cytogenetics analysis. Seventeen percent (1/6) and 86% (18/21) of patients with good- and poor-risk cytogenetic

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

findings, respectively, had lower TGIF1 expression. In contrast, TGIF1 expression was more evenly distributed in patients with a normal karyotype. Specifically, 41% (11/27) had higher and 59% (16/27) lower TGIF1 mRNA than reference, and individuals in the intermediate-risk group with lower TGIF1 survived for significantly shorter times (median survival = 201 days, CI = 138-263 days) than those with higher expression (median survival = 1566 days). TGIF1 expression also correlated with shorter OS for patients in poor-risk patients (data not shown) and even for the good-risk group, although the number of patients was small. Thus, TGIF1 levels correlated with clinical outcome in adult AML patients from all three cytogenetic risk groups. TGIF1 expression correlated with survival in independent cohorts of AML patients. To substantiate the association between TGIF1 expression and survival observed in the discovery group, we reanalyzed hybridization data from a published study <sup>23</sup> and related leukemia cell TGIF1 expression to survival in this larger (n = 285) group of patients. When patients were segregated into 5 groups according to myeloblast TGIF1 RNA abundance and trend and log-rank analysis of survival in these patients was carried out, a concentration- or dose-dependence in survival was observed (Figure 2B). We also investigated whether TGIF1 expression differed in five patient clusters, 5, 9, 10, 12, and 13<sup>23</sup>. Cluster 5 consisted of FAB class M4 or M5 leukemias, cluster 10 expressed the EVII oncogene, and clusters 9, 12 and 13 were defined by the presence of (inv)16, t(15;17), and t(8;21), respectively. Consistent with the association of t(15;17), t(8;21), and inv(16) with a better outcome and the inverse association between EVII expression and survival <sup>14</sup>, OS was shorter in patients in clusters 5 and 10 compared to 9, 12, and 13  $^{23}$  (Figure 2B). Mean *TGIF1* levels differed significantly between these clusters (P < 0.0001),

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

with significant inter-group differences noted between clusters 5 and 9 (P = 0.0001), 5 and 12 (P = 0.0001), 6 and 12 (P = 0.0001), 7 and 12 (P = 0.0001), 6 and 12 (P = 0.0001). < 0.0001), 5 and 13 (P < 0.0001), 10 and 12 (P < 0.0001), and 10 and 13 (P = 0.0003). Finally, OS was significantly worse in AML patients from The Cancer Genome Atlas (TCGA) whose TGIF1 expression was below the median than those with expression above the median for both probe set 1566901 at (P < 0.0001) and 203313 s at (P = 0.000254)(http://servers.binf.ku.dk/bloodspot/?gene=TGIF1&dataset=normal human v2 with AMLs) (Supplemental Figure S1). This association was specific for TGIF1, as there was no difference in survival according to expression of the related TGIF2 gene. Thus, analysis of multiple, independent groups of patients confirmed the correlation between TGIF1 gene expression and outcome and, for the European cohort, the quantitative nature of this relationship. TGIF1 expression was unrelated to the presence of FLT3 gene mutations. To determine whether decreased TGIF1 expression was related to FLT3 mutation, a widely used prognostic factor in adults with AML, RNA from patient cells and the MV4-11 cell line, used as a positive control for the FLT3 ITD <sup>24</sup>, were characterized by RT-PCR analysis. Of the 55 patients from whom material was available for analysis, a FLT3 ITD was detected in 15 (27%) and the D835Y missense mutation in two (4%). In two patients with a FLT3 ITD, no wild-type FLT3 RNA could be detected at the sensitivity of this method, and in accord with published data <sup>25</sup>, these individuals had very short survivals. In contrast, the OS of patients expressing mutant and wildtype FLT3 mRNA did not differ significantly from patients expressing only wild-type message in our analysis (not shown). Importantly, no association between level of TGIF1 expression and FLT3 mutation could be discerned (data not shown). These data thus argue against a model in which mutational activation of FLT3 signaling represses TGIF1 expression.

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

Reduced TGIF1 expression in myeloid leukemia cells was not associated with sequence *variants.* The association between decreased TGIF1 expression and shorter survival could be compatible with a tumor suppressor function for this transcription factor. Since wellcharacterized loss-of-function mutations in this gene have been described in a human genetic disorder, we undertook analysis of TGIF1 coding and 5' untranslated sequence for these or other mutations in 49 patients in the discovery group. Although non-synonymous as well as synonymous sequence variants were detected in 18 patients (37%), with previously unreported single nucleotide polymorphisms found in five (Supplemental Table S2), none of these corresponded to the mutations observed in patients with holoprosencephaly. Likewise, Southern blot analysis did not reveal TGIF1 gene rearrangements in any patient studied (data not shown). Thus, no definite abnormality in either gene sequence or structure was detected in any individual with AML. When TGIF1 mRNA abundance in myeloblasts was examined in aggregate, expression appeared to vary in continuous fashion (Supplemental Figure S2). TGIF1 expression in 100 lymphoblastoid cell lines derived from normal individuals likewise appeared to be a continuous variable, with an approximately 200-fold difference between the lowest and highest expresser (Supplemental Figure S3). Tgif1 gene loss decreased survival in an experimental model of acute myeloid leukemia. Given our finding that TGIF1 expression correlated significantly with survival in AML, we sought to determine if myeloblast TGIF1 abundance affected any aspect of leukemia cell biology. Our previous study has shown that Tgif1 inactivity promotes the quiescence and the self-renewal

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

activity of hematopoietic stem cells (HSC) without disturbing steady-state hematopoiesis using a TgifI knockout model<sup>26</sup>. To understand the role of TgifI in leukemia cells, in the present study, AML was induced by introduction of an MLL-AF9 fusion cDNA. Specifically, lineage-negative bone marrow cells (BMCs) from Tgif1<sup>+/+</sup> and Tgif1<sup>-/-</sup> mice were transduced with the MLL-AF9-GFP retrovirus and transduced cells transplanted into sub-lethally irradiated recipients via tail vein injection. Development and progression of leukemia in recipient mice was then monitored by flow cytometry analysis of green fluorescent protein (GFP)-expressing nucleated cells in peripheral blood. Six weeks post-transplant, mice transplanted with Tgifl--- BMCs showed higher numbers of GFP<sup>+</sup> myeloid (CD11b<sup>+</sup> and Gr-1<sup>+</sup>) cells (Figure 3A and 3B) but lower numbers of B cells (Figure 3C) compared to mice transplanted with  $Tgifl^{+/+}$  BMCs. Necropsy showed that all mice with circulating donor-derived leukemia cells had splenomegaly, with massive infiltration of myeloblasts observed in both spleen and bone marrow (data not shown). Importantly, Kaplan-Meier analysis showed that mice transplanted with MLL-AF9transduced Tgifl<sup>-/-</sup>BMCs survived a significantly shorter time than mice transplanted with transduced  $Tgifl^{+/+}$  BMCs (Figure 4). As mice transplanted with either  $Tgifl^{+/+}$  or  $Tgifl^{-/-}$  BMCs succumbed to leukemia with very short latency, the aggressive nature of this leukemia almost certainly underestimated the potential effect of Tgifl gene loss on survival and LSC number (see below). Regardless, these results are consistent with the patient data (Figures 1 and 2) and indicate that *Tgif1* abundance impacts progression of MLL-AF9-induced AML. Tgif1 gene loss increased leukemia initiating cell frequency in MLL-AF9-induced AML. LICs are thought to be crucial for the maintenance of AML in vivo 27-29. Therefore, one explanation for the shorter survival seen with Tgifl loss could be higher numbers of leukemia initiating cells. To

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

investigate, we carried out limiting dilution analysis of LIC number, transplanting serial numbers of MLL-AF9-transduced Tgif1<sup>+/+</sup> or Tgif1<sup>-/-</sup> spleen cells from primary recipients into nonconditioned C57BL/6J mice. Indeed, there was a two-fold higher frequency of LICs in Tgif1-/mice with AML (1 in 125) (95% CI: lower; 1 in 279 and higher; 1 in 56.5) than in  $Tgifl^{+/+}$  mice (1 in 250) (95% CI: lower; 1 in 603 and higher; 1 in 103.6). These data suggest that Tgif1<sup>-/-</sup> leukemic populations were enriched in LIC function and/or number. Consistent with this notion, mice transplanted with Tgifl<sup>-/-</sup> leukemia cells over a range of doses had inferior survival compared to mice transplanted with  $Tgifl^{+/+}$  cells (Figure 5 A-D). Tgif1 loss resulted in earlier relapse and more aggressive disease. Since leukemia cell preparations from Tgif1<sup>-/-</sup> mice contained higher frequencies of LICs, we predicted that disease induced by these cells would relapse earlier and progress more rapidly after treatment than disease in mice receiving  $Tgifl^{+/+}$  leukemia cells. To simulate the clinical setting, we transplanted Tgif1+/+ and Tgif1-/- MLL-AF9-transformed-spleen cells from mice with established leukemia into sub-lethally irradiated recipients and treated these mice with cytarabine and doxorubicin chemotherapy as described  $^{30}$ . For mice transplanted with  $Tgifl^{-/-}$  leukemia cells, GFP-expressing cells appeared earlier and in higher numbers in peripheral blood than in mice transplanted with  $Tgifl^{+/+}$  leukemia cells (Figure 6A). While treatment extended survival of both Tgifl<sup>+/+</sup> and Tgifl<sup>-/-</sup> mice with AML (compare Figure 6B to Figure 5D), mice transplanted with  $Tgifl^{-/-}$  leukemia cells still had shorter survival than mice transplanted with  $Tgifl^{+/+}$  leukemia cells (Figure 6B). Although selection at the level of a stem cell is not proven by these data, the differences in latency of disease and response to chemotherapy, we posit, are due to the higher

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

frequency and/or greater fitness of LICs and more rapid expansion of leukemia in Tgif1<sup>-/-</sup> mice (see Figure 6A). Tgif1 loss decreased survival in a model of chronic myeloid leukemia. Given data suggesting Tgifl expression impacted survival in AML, we went on to investigate whether Tgifl loss also affected leukemia cell biology in a mouse model of CML, a disease for which there is arguably the greatest evidence for a malignant stem cell. To that end, lineage marker-negative (Lin<sup>-</sup>) BMCs from Tgif1<sup>+/+</sup> and Tgif1<sup>-/-</sup> mice were transduced with the BCR-ABL-GFP retrovirus, which were transplanted into sub-lethally or lethally irradiated recipient mice. After transplant, leukemia progression was monitored from the kinetics of GFP-expressing myeloid cells in peripheral blood (PB) of recipient mice. Six weeks post-transplant, Tgif1-/- mice showed higher numbers of GFP<sup>+</sup> cells in PB and BM, including the LSK population, compared to Tgifl<sup>+/+</sup> mice (Supplemental Figure S4 A, B & C, respectively). Kaplan-Meier analysis revealed that mice transplanted with BCR-ABL-GFP-transduced Tgif1-/- BMCs showed significantly shorter survival than mice transplanted with BCR-ABL-GFP transduced *Tgif1*<sup>+/+</sup> BMCs (Figure 7A). When recipient mice were conditioned with a lower dose of irradiation, leukemia developed with a longer latency; however, *Tgif1* genotype still significantly impacted survival (Figure 7B). Interestingly, mice transplanted with BCR-ABL-transduced haploinsufficient (Tgif1<sup>+/-</sup>) BMCs also had shorter survivals (Supplemental Figure S5), consistent with the greater long-term repopulating ability of  $Tgifl^{+/-}$  HSCs compared to  $Tgifl^{+/+}$  HSCs after transplantation<sup>26</sup>. In sum, these data are compatible with the patient and mouse AML data and suggest *Tgif1* expression could also impact survival in CML.

Tgif1 gene loss affected multiple transcriptional networks in AML. To gain insight into the biological and molecular pathways affected by Tgifl gene loss, we compared global gene expression profiles in Tgif1-/- and Tgif1+/+ myeloid leukemia cells using RNA-seq analysis. We identified at least 45 genes that were differentially expressed in these two populations – 33 of these were significantly upregulated and 12 were down-regulated in Tgif1<sup>-/-</sup> relative to Tgif1<sup>+/+</sup> leukemia cells (Table 1). Ingenuity Pathway Analysis (IPA) allowed us to interrogate which upstream regulators contributed to gene expression changes. In this analysis, genes involved in TGF-β signaling were significantly enriched (Figure 8). Other regulators identified by this analysis included all-trans retinoic acid (ATRA) ( $P = 1.02 \times 10^{-8}$ ) and serum response factor (SRF) ( $P = 5.34 \times 10^{-6}$ ). Like the TGF-\beta targets, genes activated by ATRA were upregulated by Tgifl loss, consistent with this transcription factor's action as a corepressor of retinoic acid receptor (RAR)-dependent transcription. Genes important for embryonic stem cell pluripotency were highlighted in IPA canonical pathway analysis ( $P = 5.88 \times 10^{-4}$ ) (Supplemental Figure S6), while hematological system development and function (P =  $1.05 \times 10^{-7}$ ) was enriched in IPA physiological functions, unsurprising given the cellular source of these RNAs. Other functions impacted by Tgif1 expression included cellular movement (P =  $1.99 \times 10^{-9}$ ), leukocyte function (P =  $3.87 \times 10^{-8}$ ), cell death and survival ( $P = 5.38 \times 10^{-8}$ ), myeloid cell function ( $P = 3.24 \times 10^{-8}$ ), and cancer ( $P = 3.24 \times 10^{-8}$ ).  $2.63 \times 10^{-7}$ ). In summary, pathway analysis in Tgif1 knockout leukemia cells revealed upregulation of TGF-β signaling, with potentially important consequences for LSC function.

## Discussion

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

Our studies revealed that expression of the transcriptional regulator TGIF1 correlates quantitatively with survival in adults with AML treated with standard induction and consolidation chemotherapy, a finding that was validated in two other, independent cohorts of patients. TGIF1 expression impacted outcome in each cytogenetic risk group, and, at least for patients treated at our institution, was an independent risk factor in multivariate analysis. Consistent with these results, we found that loss or haploinsufficiency of this gene accelerated leukemia development, impaired response to chemotherapy, and reduced survival in mouse models of acute and chronic myeloid leukemia. Whether quantification of TGIF1 expression will have clinical utility in risk stratification in patients with AML, however, requires further investigation. TGIF1 belongs to the TALE family of homeodomain proteins <sup>21</sup> and functions as a corepressor of retinoic acid and TGF-β-stimulated transcription. It does so by interfering with retinoid X receptor (RXR) binding to DNA and recruiting general corepressors <sup>31</sup> and promoting recruitment of histone deacetylases to the TGF-β signaling intermediate Smad2 <sup>20-22, 32</sup>, respectively. TGIF1 can also inhibit transcription directly through binding to a TG-rich sequence element via its homeobox domain. Inactivating mutations in TGIF1 cause autosomal dominant holoprosencephaly <sup>33-36</sup>, the most common inherited defect in forebrain development in humans, while inactivation of the *Tgif1* gene in mice, complete or partial, increases quiescence in bone marrow HSCs and enhances long-term repopulating activity without an effect on steady-state hematopoiesis  $^{26}$ . In light of studies demonstrating that LSC frequency at diagnosis in AML correlates with increased minimal residual disease and poor survival <sup>37</sup>, the finding that reduced or absent expression of Tgif1 in mouse models of myeloid leukemia enhanced LSC function provides at

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

least one explanation for how it affects recurrence. Since effective therapy after relapse is lacking in AML, except for hematopoietic stem cell transplantation in the case when a second remission can be induced, this explains how patient survival would be impacted. We found using a mouse model of AML that loss of *Tgif1* resulted in a shorter latency in development of leukemia, earlier relapse after chemotherapy, and inferior survival. In addition, we found in a model of CML that heterozygous as well as homozygous loss of Tgifl shortened survival. These results underscore the quantitative relationship between TGIF1 abundance and survival in AML patients and stem cell frequency in mice. They are also compatible with a recent report demonstrating that enforced expression of TGIF1 decreased leukemia cell proliferation, induced terminal differentiation, and increased survival in MLL-AF9 leukemia <sup>38</sup>. Altogether, these data establish a biological basis for the association between TGIF1 expression and clinical outcome. In accord with its function as transcriptional repressor or corepressor, RNA expression profiling identified a number of genes that were upregulated in *Tgif1*-null leukemia cells, with almost half the genes differentially expressed in knockout and wild-type leukemia cells involved directly or indirectly in TGF-β signaling (Supplemental Figure 6). This result also corroborates the enhanced TGF-β signaling and/or target gene expression noted in epithelial <sup>32</sup> and myeloid leukemia cells <sup>39</sup> in which TGIF1 expression was reduced by RNA interference. Importantly, expression of the prototypic TGF-β target gene, plasminogen activator inhibitor-1, in human myeloid leukemia cells correlated significantly with expression of a type I TGF-β receptor, activin receptor-like kinase-5 (ALK-5), and presumably downstream signaling strength. Likely for the reason offered here, ALK-5 expression, in turn, correlated inversely with achievement of CR and with EFS, RFS, and OS <sup>40</sup>.

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

Relevant to this work, TGF-β was shown to promote self-renewal in human HSCs <sup>41</sup> and quiescence in murine HSCs <sup>42</sup> and to enhance the function of leukemia stem cells <sup>41, 43-55</sup>, which could also explain the curative potential of a small-molecule inhibitor of the type I TGF-\(\beta\) receptor <sup>56, 57</sup> added to a BCR-ABL tyrosine kinase inhibitor in CML in mice <sup>51</sup>. Together with the gene expression results, these studies predict, therefore, that a TGF-β signaling inhibitor, most logically used in combination with post-remission chemotherapy, would have the greatest impact in patients with the lowest TGIF1 expression. In addition to an effect on TGF-β target gene expression, loss of TGIF1 caused apparent derepression of retinoic acid receptor (RAR) target genes, consistent with its ability to act as a corepressor of RAR/RXR-mediated transcription. Finally, our results do not exclude direct effects of TGIF1 on gene expression or indirect effects through interaction with other TALE homeodomain proteins, MEIS1 for example <sup>38</sup>. As chemical inhibitors are available for TGF-β or RAR signaling, it should be possible to determine which of these signaling pathways is most important for TGIF1's actions in leukemia cells. It will also be important to determine whether inhibition of these pathways, and TGF-β in particular, would have equivalent biological effects on leukemic compared to normal stem cells, which would have therapeutic implications. Although loss-of-function mutations in *TGIF1* have been recognized in holoprosencehaly <sup>35</sup>, <sup>36</sup>, we did not observe any coding or promoter mutations or any structural rearrangements of the gene in AML patients. Furthermore, individuals with holoprosencephaly and Tgifl-null mice are not at increased risk for development of myeloid leukemia, all of which argues against a function of this protein as a tumor suppressor. Its graded expression in hematopoietic cells and dosedependent effect on cell function, most clearly demonstrated for normal HSCs <sup>26</sup>, suggest that TGIF1 acts as a quantitative trait locus in normal and malignant stem cell biology. In addition,

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

TGIF1 exemplifies a type of cancer modifier gene that affects disease progression and persistence rather than pathogenesis. In summary, by relating transcriptional profiles in myeloblasts from patients with AML to survival, we have identified a new prognostic marker relevant, potentially, to all myeloid leukemias. In addition, TGIF1 may be the prototype of a stem cell modifier gene, operating not in the initiation of leukemia but in disease progression and persistence. **Materials and Methods Patients.** Pre-treatment samples from 60 patients with AML treated at Vanderbilt University Hospital or Nashville VA Medical Center from 1996-2000 were obtained with the informed consent of patients and approval of the responsible Institutional Review Board (Supplemental Table 1) 47. A diagnosis of AML was made by examination of blood and/or bone marrow with cytochemical stains and with cytogenetics and flow cytometry analysis. Mononuclear cells were enriched by Ficoll-Hypaque centrifugation, depleted of T-cells and monocytes with antibodies to CD2 and CD14 (Dynal Biotech, Brown Deer, WI), respectively, and stored frozen at -80°C. Anti-CD2-conjugated beads alone were used for leukemias of FAB classes M4 and M5. Classification by cytogenetic risk group. Patients were risk-stratified according to the results of cytogenetics analysis. The good-risk group was defined by the presence of t(8;21), t(15;17), or inv(16) and poor-risk group by del(5), del(7), t(6,9), alterations in 11q23, or multiple cytogenetic abnormalities. Patients with normal karyotypes were assigned to the intermediate-risk group.

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

Survival analysis in patients. Gene expression profiles were related to individual patient survival. Modified Cox PH regression analysis was used to rank genes by ability to predict OS, with the importance of individual genes weighted in accordance with the data available. Survival analysis in the discovery group was carried out using SPSS version 22 (Chicago, IL). Patients were enrolled between 1996 and 2001 and their outcomes last updated on June 6, 2004. OS was calculated from the time of initial diagnosis (n = 53) or relapse (n = 7) to last follow-up or death. Survival was analyzed as a function of TGIF1 expression using both normalized hybridization and real-time PCR data. For the original microarray analysis, TGIF1 expression in leukemia cells was divided by that in a commercial reference, log<sub>2</sub> transformed, and related to patient survival. Kaplan-Meier plots were analyzed with a log-rank test. P values were based on two-sided comparisons, with P < 0.05 considered significant. RFS was calculated from the time of diagnosis to documented relapse, SCT, death, or last follow-up. Patients who failed to achieve a CR were considered to have an RFS of 0 and all untreated patients were excluded. As described below, the patient cohort described in the study by Valk et al <sup>23</sup> was subdivided into five groups according to leukemia cell TGIF1 expression and the actuarial probabilities of OS and event-free survival (EFS) were estimated from Kaplan-Meier analysis (Stata Statistical Software, release 9.2; College Station, TX). Trend and log-rank analysis were carried out using Microsoft Excel (Redmond, WA). Hybridization data were normalized with MAS 5.0, log<sub>2</sub>-transformed TGIF1 expression ratios were median-centered, and differences in TGIF1 expression between clusters 5, 9, 10, 12, and 15 were assessed by one-way analysis of variance (SAS, Cary, NC). **Treatment.** Ninety four percent (50/53) of newly diagnosed patients received induction chemotherapy, with 82% (41/50) treated with 100 mg/m<sup>2</sup>/day of cytarabine by continuous

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

infusion from days 1-7 and 12 mg/m<sup>2</sup> of idarubicin or 45 mg/m<sup>2</sup> daunorubicin intravenously on days 1-3. Two other patients received cytarabine for five days instead of seven. Most of the remaining patients received cytarabine and an anthracycline together with other agents. Five patients received an induction regimen of dexamethasone, cytarabine, thioguanine, etoposide, and daunorubicin. Four patients with *de novo* disease did not receive induction chemotherapy, while three of seven patients with relapsed leukemia received salvage therapy. Ouantitative real-time PCR analysis. Total cellular RNA (1 μg) was transcribed into cDNA with a mixture of random hexamer and oligo(dT) primers (iScript cDNA Synthesis Kit. Bio-Rad, Hercules, CA). Real-time PCR analysis was carried out using SYBR Green I detection (iTaq SYBR Green Supermix and MyiQ Single-Color Real-Time PCR Detection System, Bio-Rad). Amplification parameters consisted of an initial denaturation at 95°C for 3 min. This was followed by 35 cycles of denaturation at 94°C for 30 seconds, annealing at 56.7°C for 30 seconds, and extension at 75°C for 10 seconds. TGIF expression in leukemia samples was quantified with the same reference RNA employed for the microarray studies, and relative quantification of glyceraldehyde phosphate dehydrogenase (GAPDH) gene expression was performed identically. Threshold cycles (C<sub>T</sub>) were determined for *GAPDH* and *TGIF*, and if the GAPDH C<sub>T</sub> differed by three cycles or more between blast cell and reference cDNA, the concentration and quality of RNA in that patient's sample was reevaluated. Four of the five samples to which this applied were subsequently used after repeat determination of RNA concentration. Primers were designed using the MacVector software package (Accelrys, San Diego, CA). The sequences of the primers used in this analysis were: forward TGIF primer CAGATTCTTCGGGATTGGCTG, reverse *TGIF* primer

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

GGCGTTGATGAACCAGTTACAGAC, forward GAPDH primer AATCCCCAGTGCTCCTTTTC, reverse *GAPDH* primer CAAAGTTGTCATCGATGACC. TGIF mutational analysis. cDNA synthesis was carried out with the Superscript First-Strand System (Invitrogen Life Technologies, Carlsbad, CA) using 1 µg of total cellular RNA and an oligo(dT) primer. One-tenth volume of the first-strand reaction was then used as template for PCR amplification (Elongase Amplification System, Invitrogen). The sequences of the primers used in this analysis, corresponding to nucleotides 25-45 and 1489-1509, respectively, of TGIF RNA sequence, were: forward primer GCAGGAGCAGGAACAAAG, reverse primer CAGTATGTGGGCATCCTGTTC. Amplification parameters consisted of an initial denaturation at 94°C for 3 min, annealing at 56°C for 30 seconds, and extension at 72°C for 1 minute. This was followed by 35 cycles of denaturation at 94°C for 30 seconds, annealing at 56°C for 30 seconds, and extension at 68°C for 90 seconds and, terminally, extension at 68°C for 5 minutes. The resulting 1,477 bp cDNA product was purified in a Microcon 50 microconcentrator (Amicon, Danvers, MA) and an aliquot visualized by ethidium bromide staining after electrophoresis in a 1% agarose gel. Automated sequencing of purified PCR products was carried out with a BigDye Terminator cycle sequencing kit (v3.1, Applied Biosystems) using sets of primer encompassing the complete TGIF coding sequence. All sequence variants were confirmed by sequencing of both strands. FLT3 mutational analysis. The presence of an ITD or D835Y kinase domain mutation in FLT3 was determined by reverse transcription-polymerase chain (RT-PCR) analysis of leukemic cell RNA. Total cellular RNA was purified using the RNeasy purification system (Qiagen) from

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

blasts obtained as described above. RNA was reverse transcribed using an iScript cDNA Synthesis kit according to the manufacturer's (Bio-Rad) instructions, and one-tenth volume of the RT mixture was used for PCR amplification. The sequences of the primers used in this analysis were: forward ITD TGGTGTTTGTCTCTCTTCATTGTCG, reverse ITD TCTTTCAGCATTTTGACGGCAACC, forward D835Y GAAGAAGAGGAGGACTTGAATGTGC, reverse D835Y AGGTCGCCTGTTTTGGTAGGTG. PCR was carried out with TaKaRa LA Tag polymerase (TaKaRa Mirus Bio, Madison, WI) in a 50 μl reaction volume containing 1× PCR buffer, 2mM MgCl<sub>2</sub>, 0.4 mM of each dNTP, 0.2 µM of each primer, and 2.5 U of enzyme. Amplification parameters consisted of an initial denaturation at 94°C for 3 min, annealing at 56°C for 30 seconds, and extension at 72°C for 1 minute, followed by 30 cycles of denaturation at 94°C for 30 seconds, annealing at 56°C for 30 seconds, and extension at 72°C for 1 minute. PCR products were digested with EcoRV for 1 hour at 37°C for detection of the D835Y mutation. Amplified fragments and EcoRV-digested products were analyzed on a 3% NuSieve-agarose gel (Cambrex, Rutherford, NJ), with a FLT3 ITD recognized from an increase in the size of the amplified fragment (>300 bp) and the D835Y mutation by the absence of *Eco*RV digestion. Evaluation of remission. Bone marrow aspiration and biopsy were carried out on days 14 and 28 of therapy to assess response. CR was defined as the disappearance of leukemia cells from the bone marrow accompanied by return of normal blood counts. For patients with antecedent MDS, CR was defined as recovery of pre-leukemic numbers, with blasts making up  $\leq 5\%$  of nucleated bone marrow cells.

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

*Mice and plasmids*. Mice with a *Tgif1* null mutation have been previously described <sup>26</sup>. C57BL/6J mice were purchased from the Jackson Laboratories (Bar Harbor, ME). All animal experiments were approved by the Animal Care and Use Committees of Vanderbilt University and University of Virginia. MSCV-MLL-AF9-IRES-GFP vector was provided by Dr. Scott Armstrong (Memorial Sloan-Kettering Cancer Center, New York, NY) and MSCV-BCR/ABL-IRES-GFP vector was provided by Dr. Michael Engel (University of Utah, Salt Lake City, UT). **Retrovirus production.** Retroviral vectors were transfected into Phoenix ecotropic retroviral packaging cells using Lipofectamine 2000 according to the manufacturer's instructions. Fortyeight hours after transfection, viral supernatants were collected, filtered, and stored at -80°C. Induction of myeloid leukemia in mice. The MSCV-MLL-AF9-IRES-GFP retrovirus was used to induce AML in mice. Bone marrow cells were flushed from the tibias and femurs of  $Tgifl^{+/+}$ or Tgifl<sup>-/-</sup> mice and lineage marker-negative (Lin<sup>-</sup>) cells were enriched using the Mouse Lineage Cell Depletion kit (Miltenyi Biotec, San Diego, CA). Lin cells purified from Tgifl+/+ or Tgifl-/mice were then transduced using low-speed centrifugation, or spinoculation, with MSCV-MLL-AF9-IRES-GFP retrovirus in the presence of 8  $\mu$ g/ml polybrene at 1350g × 45 min (32°C). Transduced  $Tgifl^{+/+}$  or  $Tgifl^{-/-}$  Lin<sup>-</sup> cells were resuspended in phosphate-buffered saline (PBS) and  $1 \times 10^5$  cells were injected intravenously into sub-lethally irradiated (4.5 Gy)  $Tgif1^{+/+}$  or Tgif1-/- recipient mice, respectively. Reconstitution of transduced cells in recipient mice was evaluated by monitoring GFP expression in flow cytometry (FACS) analysis at 1-2 week intervals following transplantation. Recipient mice were euthanized for analysis when they developed palpable splenomegaly or appeared ill. Bone marrow and spleen cells from leukemic mice were isolated and stored frozen for later use.

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

The MSCV-BCR/ABL-IRES-GFP retrovirus was used to induce CML in mice. Bone marrow cells were flushed from the tibias and femurs of  $Tgifl^{+/+}$ ,  $Tgifl^{+/-}$ , or  $Tgifl^{-/-}$  mice and single-cell suspensions of Lin c-Kit+ cells were obtained using the Mouse Lineage Cell Depletion kit and CD117 microbeads (Miltenyi Biotec, San Diego, CA). Lin<sup>-</sup> c-Kit<sup>+</sup> cells were spinoculated with MSCV-BCR/ABL-IRES-GFP retrovirus in the presence of 8 µg/ml polybrene for 45 minutes at 1350g (32°C). Transduced cells were resuspended in PBS and  $8 \times 10^4$  cells were injected intravenously into lethally or sub-lethally irradiated C57BL/6J recipient mice. Reconstitution of transduced cells in recipient mice was evaluated by FACS analysis of GFP expression two weeks after transplantation. Mice were monitored for development of disease as described above, at which time they were euthanized. Quantification of leukemia-initiating cell frequency. Leukemia cells from spleens of three Tgif1+/+ or three Tgif1-/- mice with AML induced with the MSCV-MLL-AF9-IRES-GFP retrovirus were pooled, and  $1 \times 10^6$ ,  $1 \times 10^5$ ,  $1 \times 10^4$ ,  $1 \times 10^3$ , 100, and 50 cells were transplanted into sub-lethally irradiated recipients. Animals were euthanized when they became visibly ill and the development of leukemia was confirmed. LIC frequency was determined by limiting dilution analysis with the ELDA (for Extreme Limiting Dilution Analysis) software package <sup>58</sup>. Chemotherapy studies in AML mice. For treatment studies,  $2 \times 10^3$  splenic leukemia cells from Tgifl<sup>+/+</sup> or Tgifl<sup>-/-</sup> mice were transplanted into sub-lethally irradiated recipients by tail vein injection. Two weeks after transplant, mice were treated by intraperitoneal injection with 100 mg/kg cytarabine once per day for five days and 3 mg/kg doxorubicin for three days. Mice were

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

monitored closely for disease development and GFP expression was evaluated weekly by FACS analysis. Animals were euthanized when they appeared ill and transfer of disease was verified. RNA sequencing (RNA-seq) analysis of AML cells. RNA was extracted from sorted populations of GFP-expressing leukemia cells isolated from the bone marrow or spleen of Tgifl<sup>+/+</sup> or Tgifl<sup>-/-</sup> mice with AML (3 replicates each). RNA-seq and bioinformatics analysis was performed in the Vanderbilt Technologies for Advanced Genomics (or VANTAGE) Shared Resource. Sequence data were annotated with the University of California, Santa Cruz Genome Browser (https://genome.ucsc.edu/), and the TopHat and Cufflinks software packages were used for transcript alignment and quantification of gene expression. Gene set enrichment analysis <sup>59</sup> was carried out using the default weighted enrichment statistic to test whether differentially expressed genes (between Tgifl<sup>+/+</sup> and Tgifl<sup>-/-</sup> LSK cells) were randomly distributed or enriched at the top or bottom of the gene list. A false discovery rate of  $\leq 0.25$  was considered significant. Ingenuity Pathway Analysis (<a href="http://www.ingenuity.com/">http://www.ingenuity.com/</a>) was performed to group functionally related genes and assign them to biological pathways. RNA preparation and cDNA microarray analysis. Leukemic blasts from heparinized bone marrow or peripheral blood were enriched by Ficoll-Hypaque gradient centifugation, depleted of T lymphocytes and monocytes using magnetic beads (Dynal Biotech, Brown Deer, WI) conjugated with monoclonal antibodies to CD2 and CD14, respectively, and immediately cryopreserved. In the case of myelomonocytic (FAB M4) or monocytic (M5) leukemias, only the CD2 antibody was used. All cell populations contained at least 95% blasts and had an initial viability of ≥90%. Total cellular RNA was prepared from thawed cells on silica-gel membranes

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

with on-column DNAse treatment (RNeasy Total RNA Isolation Kit, Qiagen, Valencia, CA). RNA integrity was assessed with an Agilent Bioanalyzer (Agilent Technologies, Palo Alto, CA), and samples showing evidence of degradation were discarded. Fluorescent labeling of probes was carried out in the Microarray Shared Resource of the Vanderbilt-Ingram Cancer Center, with incorporation of amino-allyl dUTP during reverse transcription and reaction of the amine-modified cDNA with monofunctional forms of Cy3 and Cy5 dyes. Dye-labeled cDNAs were then hybridized to glass slides that had been robotically spotted with an 11,000-element human cDNA library, and fluorescence intensity was measured with an AXON or GSI Lumonics dual laser scanner. Leukemic cell cDNAs were competitively hybridized with cDNA generated from a commercial reference RNA (Universal Human Reference RNA, Stratagene, La Jolla, CA) derived from a mixture of ten human cell lines. The ratio of transcript abundance in experimental samples to the RNA reference was first transformed by log<sub>2</sub>. Normalization of hybridization signals was then carried out with GeneTraffic software (Iobion, La Jolla, CA) using the following parameters: signal to background intensity <1.3, Cy3 intensity <150, and Cy5 intensity < 200. Acknowledgements This work was supported by National Institutes of Health grants K08 HL089903 (to R.H.) and P30 CA068485 (to Vanderbilt-Ingram Cancer Center) and American Cancer Society Scholar Award RSG LIB-118462 (to R.H). We thank Drs. Ruud Delwel, Sanne Lugthart, and Bob Löwenberg for making available and analyzing microarray data from the Erasmus University study, Scott Boswell and Scott Armstrong for provision of materials, and Craig Jordan and Scott Hiebert for helpful discussions.

**Author Contributions** 

535

536

543

544

549

550

561562

563

564

565

566

567

- 537 L.Y., J.A.M.-P., R.H. and S.J.B. conceived the studies. V.D.K., J.P.G., U.P.D. and D.W.
- provided study materials or patients. L.Y., J.A.M.-P., R.H., and D.M., collected and/or
- assembled data. L.Y., R.H., Y.S., J.P.G., U.P.D., M.J.K., D.W. and S.J.B. contributed to data
- analysis and interpretation. L.Y., J.A.M.-P., R.H. and S.J.B. drafted the manuscript. All authors
- gave final approval of the manuscript.
- 542 **Conflict of Interest** The authors declare that they have no conflict of interest.

#### References

- [1] Kadia, T. M., Ravandi, F., O'Brien, S., Cortes, J., and Kantarjian, H. M. (2015) Progress in acute myeloid leukemia, *Clin Lymphoma Myeloma Leuk 15*, 139-151.
- [2] Lengfelder, E., Hofmann, W. K., and Nolte, F. (2013) Management of elderly patients with acute promyelocytic leukemia: progress and problems, *Ann Hematol 92*, 1181-1188.
  - [3] Estey, E. H. (2014) Acute myeloid leukemia: 2014 update on risk-stratification and management, *Am J Hematol 89*, 1063-1081.
- 551 [4] Liersch, R., Muller-Tidow, C., Berdel, W. E., and Krug, U. (2014) Prognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use, *Br J Haematol 165*, 17-38.
- [5] Giles, F. J., Keating, A., Goldstone, A. H., Avivi, I., Willman, C. L., and Kantarjian, H. M. (2002) Acute myeloid leukemia, *Hematology Am Soc Hematol Educ Program*, 73-110.
- 556 [6] Lowenberg, B. (2001) Prognostic factors in acute myeloid leukaemia, *Best Pract Res Clin Haematol* 14, 65-75.
- 558 [7] Ghanem, H., Tank, N., and Tabbara, I. A. (2012) Prognostic implications of genetic 559 aberrations in acute myelogenous leukemia with normal cytogenetics, *Am J Hematol* 87, 560 69-77.
  - [8] Slovak, M. L., Kopecky, K. J., Cassileth, P. A., Harrington, D. H., Theil, K. S., Mohamed, A., Paietta, E., Willman, C. L., Head, D. R., Rowe, J. M., Forman, S. J., and Appelbaum, F. R. (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study, *Blood 96*, 4075-4083.
  - [9] Drobyski, W. R. (2004) The role of allogeneic transplantation in high-risk acute myelogenous leukemia, *Leukemia 18*, 1565-1568.
- [10] Kottaridis, P. D., Gale, R. E., Frew, M. E., Harrison, G., Langabeer, S. E., Belton, A. A.,
   Walker, H., Wheatley, K., Bowen, D. T., Burnett, A. K., Goldstone, A. H., and Linch, D.
   C. (2001) The presence of a FLT3 internal tandem duplication in patients with acute

- 571 myeloid leukemia (AML) adds important prognostic information to cytogenetic risk 572 group and response to the first cycle of chemotherapy: analysis of 854 patients from the 573 United Kingdom Medical Research Council AML 10 and 12 trials, *Blood 98*, 1752-1759.
- 574 [11] Kottaridis, P. D., Gale, R. E., and Linch, D. C. (2003) Flt3 mutations and leukaemia, *Br J Haematol 122*, 523-538.

- [12] Frohling, S., Schlenk, R. F., Breitruck, J., Benner, A., Kreitmeier, S., Tobis, K., Dohner, H., Dohner, K., and leukemia, A. M. L. S. G. U. A. m. (2002) Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm, *Blood 100*, 4372-4380.
- [13] Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schakel, U., Platzbecker, U., Wermke, M., Bornhauser, M., Ritter, M., Neubauer, A., Ehninger, G., and Illmer, T. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis, *Blood 99*, 4326-4335.
- [14] Barjesteh van Waalwijk van Doorn-Khosrovani, S., Erpelinck, C., van Putten, W. L., Valk, P. J., van der Poel-van de Luytgaarde, S., Hack, R., Slater, R., Smit, E. M., Beverloo, H. B., Verhoef, G., Verdonck, L. F., Ossenkoppele, G. J., Sonneveld, P., de Greef, G. E., Lowenberg, B., and Delwel, R. (2003) High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients, *Blood 101*, 837-845.
- [15] Inokuchi, K., Yamaguchi, H., Hanawa, H., Tanosaki, S., Nakamura, K., Tarusawa, M., Miyake, K., Shimada, T., and Dan, K. (2002) Loss of DCC gene expression is of prognostic importance in acute myelogenous leukemia, *Clin Cancer Res* 8, 1882-1888.
- [16] Baldus, C. D., Tanner, S. M., Ruppert, A. S., Whitman, S. P., Archer, K. J., Marcucci, G., Caligiuri, M. A., Carroll, A. J., Vardiman, J. W., Powell, B. L., Allen, S. L., Moore, J. O., Larson, R. A., Kolitz, J. E., de la Chapelle, A., and Bloomfield, C. D. (2003) BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study, *Blood 102*, 1613-1618.
- [17] Barjesteh van Waalwijk van Doorn-Khosrovani, S., Erpelinck, C., Meijer, J., van Oosterhoud, S., van Putten, W. L., Valk, P. J., Berna Beverloo, H., Tenen, D. G., Lowenberg, B., and Delwel, R. (2003) Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML, *Hematol J 4*, 31-40.
- [18] Frohling, S., and Dohner, H. (2004) Disruption of C/EBPalpha function in acute myeloid leukemia, *N Engl J Med 351*, 2370-2372.
- [19] Hamid, R., Patterson, J., and Brandt, S. J. (2008) Genomic structure, alternative splicing and expression of TG-interacting factor, in human myeloid leukemia blasts and cell lines, *Biochim Biophys Acta 1779*, 347-355.
- [20] Wotton, D., Knoepfler, P. S., Laherty, C. D., Eisenman, R. N., and Massague, J. (2001) The Smad transcriptional corepressor TGIF recruits mSin3, *Cell Growth Differ* 12, 457-463.
- 611 [21] Wotton, D., Lo, R. S., Lee, S., and Massague, J. (1999) A Smad transcriptional corepressor, 612 *Cell* 97, 29-39.
- [22] Wotton, D., Lo, R. S., Swaby, L. A., and Massague, J. (1999) Multiple modes of repression by the Smad transcriptional corepressor TGIF, *J Biol Chem* 274, 37105-37110.
- [23] Valk, P. J., Verhaak, R. G., Beijen, M. A., Erpelinck, C. A., Barjesteh van Waalwijk van
   Doorn-Khosrovani, S., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P.

- J., Lowenberg, B., and Delwel, R. (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia, *N Engl J Med 350*, 1617-1628.
- 619 [24] Quentmeier, H., Reinhardt, J., Zaborski, M., and Drexler, H. G. (2003) FLT3 mutations in acute myeloid leukemia cell lines, *Leukemia 17*, 120-124.
- [25] Whitman, S. P., Archer, K. J., Feng, L., Baldus, C., Becknell, B., Carlson, B. D., Carroll, A.
   J., Mrozek, K., Vardiman, J. W., George, S. L., Kolitz, J. E., Larson, R. A., Bloomfield,
   C. D., and Caligiuri, M. A. (2001) Absence of the wild-type allele predicts poor
   prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the
   internal tandem duplication of FLT3: a cancer and leukemia group B study, *Cancer Res* 61, 7233-7239.

- [26] Yan, L., Womack, B., Wotton, D., Guo, Y., Shyr, Y., Dave, U., Li, C., Hiebert, S., Brandt, S., and Hamid, R. (2013) Tgif1 regulates quiescence and self-renewal of hematopoietic stem cells, *Mol Cell Biol* 33, 4824-4833.
- [27] Kirstetter, P., Schuster, M. B., Bereshchenko, O., Moore, S., Dvinge, H., Kurz, E.,
   Theilgaard-Monch, K., Mansson, R., Pedersen, T. A., Pabst, T., Schrock, E., Porse, B. T.,
   Jacobsen, S. E., Bertone, P., Tenen, D. G., and Nerlov, C. (2008) Modeling of
   C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of
   committed myeloid leukemia-initiating cells, Cancer Cell 13, 299-310.
  - [28] Shlush, L. I., Zandi, S., Mitchell, A., Chen, W. C., Brandwein, J. M., Gupta, V., Kennedy, J. A., Schimmer, A. D., Schuh, A. C., Yee, K. W., McLeod, J. L., Doedens, M., Medeiros, J. J., Marke, R., Kim, H. J., Lee, K., McPherson, J. D., Hudson, T. J., Consortium, H. P.-L. G. P., Brown, A. M., Yousif, F., Trinh, Q. M., Stein, L. D., Minden, M. D., Wang, J. C., and Dick, J. E. (2014) Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia, *Nature* 506, 328-333.
  - [29] Taussig, D. C., Vargaftig, J., Miraki-Moud, F., Griessinger, E., Sharrock, K., Luke, T., Lillington, D., Oakervee, H., Cavenagh, J., Agrawal, S. G., Lister, T. A., Gribben, J. G., and Bonnet, D. (2010) Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction, *Blood 115*, 1976-1984.
  - [30] Zuber, J., Radtke, I., Pardee, T. S., Zhao, Z., Rappaport, A. R., Luo, W., McCurrach, M. E., Yang, M. M., Dolan, M. E., Kogan, S. C., Downing, J. R., and Lowe, S. W. (2009)

    Mouse models of human AML accurately predict chemotherapy response, *Genes Dev 23*, 877-889.
  - [31] Bertolino, E., Reimund, B., Wildt-Perinic, D., and Clerc, R. G. (1995) A novel homeobox protein which recognizes a TGT core and functionally interferes with a retinoid-responsive motif, *J Biol Chem* 270, 31178-31188.
- [32] Seo, S. R., Lallemand, F., Ferrand, N., Pessah, M., L'Hoste, S., Camonis, J., and Atfi, A. (2004) The novel E3 ubiquitin ligase Tiul1 associates with TGIF to target Smad2 for degradation, *EMBO J 23*, 3780-3792.
- [33] Ming, J. E., Kaupas, M. E., Roessler, E., Brunner, H. G., Golabi, M., Tekin, M., Stratton, R.
   F., Sujansky, E., Bale, S. J., and Muenke, M. (2002) Mutations in PATCHED-1, the
   receptor for SONIC HEDGEHOG, are associated with holoprosencephaly, *Hum Genet* 110, 297-301.
- 660 [34] Ming, J. E., and Muenke, M. (2002) Multiple hits during early embryonic development: digenic diseases and holoprosencephaly, *Am J Hum Genet 71*, 1017-1032.

- [35] Wallis, D., and Muenke, M. (2000) Mutations in holoprosencephaly, *Hum Mutat 16*, 99-108.
- 664 [36] Wallis, D. E., and Muenke, M. (1999) Molecular mechanisms of holoprosencephaly, *Mol Genet Metab* 68, 126-138.
- [37] van Rhenen, A., Feller, N., Kelder, A., Westra, A. H., Rombouts, E., Zweegman, S., van der
   Pol, M. A., Waisfisz, Q., Ossenkoppele, G. J., and Schuurhuis, G. J. (2005) High stem
   cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual
   disease and poor survival, *Clin Cancer Res 11*, 6520-6527.
  - [38] Willer, A., Jakobsen, J. S., Ohlsson, E., Rapin, N., Waage, J., Billing, M., Bullinger, L., Karlsson, S., and Porse, B. T. (2014) TGIF1 is a negative regulator of MLL-rearranged acute myeloid leukemia, *Leukemia*.

- [39] Hamid, R., and Brandt, S. J. (2009) Transforming growth-interacting factor (TGIF)
   regulates proliferation and differentiation of human myeloid leukemia cells, *Mol Oncol 3*,
   451-463.
  - [40] Otten, J., Schmitz, L., Vettorazzi, E., Schultze, A., Marx, A. H., Simon, R., Krauter, J., Loges, S., Sauter, G., Bokemeyer, C., and Fiedler, W. (2011) Expression of TGF-beta receptor ALK-5 has a negative impact on outcome of patients with acute myeloid leukemia, *Leukemia* 25, 375-379.
  - [41] Pierelli, L., Marone, M., Bonanno, G., Rutella, S., de Ritis, D., Mancuso, S., Leone, G., and Scambia, G. (2002) Transforming growth factor-beta1 causes transcriptional activation of CD34 and preserves haematopoietic stem/progenitor cell activity, *Br J Haematol* 118, 627-637.
  - [42] Yamazaki, S., Iwama, A., Takayanagi, S., Eto, K., Ema, H., and Nakauchi, H. (2009) TGF-beta as a candidate bone marrow niche signal to induce hematopoietic stem cell hibernation, *Blood 113*, 1250-1256.
  - [43] Falk, L. A., De Benedetti, F., Lohrey, N., Birchenall-Roberts, M. C., Ellingsworth, L. W., Faltynek, C. R., and Ruscetti, F. W. (1991) Induction of transforming growth factor-beta 1 (TGF-beta 1), receptor expression and TGF-beta 1 protein production in retinoic acid-treated HL-60 cells: possible TGF-beta 1-mediated autocrine inhibition, *Blood* 77, 1248-1255.
  - [44] Imai, Y., Kurokawa, M., Izutsu, K., Hangaishi, A., Maki, K., Ogawa, S., Chiba, S., Mitani, K., and Hirai, H. (2001) Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis, *Oncogene 20*, 88-96.
  - [45] Kim, S. J., and Letterio, J. (2003) Transforming growth factor-beta signaling in normal and malignant hematopoiesis, *Leukemia 17*, 1731-1737.
  - [46] Krause, D. S., Fulzele, K., Catic, A., Sun, C. C., Dombkowski, D., Hurley, M. P., Lezeau, S., Attar, E., Wu, J. Y., Lin, H. Y., Divieti-Pajevic, P., Hasserjian, R. P., Schipani, E., Van Etten, R. A., and Scadden, D. T. (2013) Differential regulation of myeloid leukemias by the bone marrow microenvironment, *Nat Med 19*, 1513-1517.
  - [47] Kurokawa, M., Mitani, K., Imai, Y., Ogawa, S., Yazaki, Y., and Hirai, H. (1998) The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells, *Blood 92*, 4003-4012.
- [48] Kurokawa, M., Mitani, K., Irie, K., Matsuyama, T., Takahashi, T., Chiba, S., Yazaki, Y.,
   Matsumoto, K., and Hirai, H. (1998) The oncoprotein Evi-1 represses TGF-beta
   signalling by inhibiting Smad3, *Nature 394*, 92-96.

- 707 [49] Marone, M., Scambia, G., Bonanno, G., Rutella, S., de Ritis, D., Guidi, F., Leone, G., and 708 Pierelli, L. (2002) Transforming growth factor-beta1 transcriptionally activates CD34 and 709 prevents induced differentiation of TF-1 cells in the absence of any cell-cycle effects, *Leukemia 16*, 94-105.
- 711 [50] Murohashi, I., Endho, K., Nishida, S., Yoshida, S., Jinnai, I., Bessho, M., and Hirashima, K. (1995) Differential effects of TGF-beta 1 on normal and leukemic human hematopoietic cell proliferation, *Exp Hematol 23*, 970-977.

- [51] Naka, K., Hoshii, T., Muraguchi, T., Tadokoro, Y., Ooshio, T., Kondo, Y., Nakao, S., Motoyama, N., and Hirao, A. (2010) TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia, *Nature* 463, 676-680.
  - [52] Siegel, P. M., and Massague, J. (2003) Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer, *Nat Rev Cancer 3*, 807-821.
  - [53] Sitnicka, E., Ruscetti, F. W., Priestley, G. V., Wolf, N. S., and Bartelmez, S. H. (1996) Transforming growth factor beta 1 directly and reversibly inhibits the initial cell divisions of long-term repopulating hematopoietic stem cells, *Blood 88*, 82-88.
  - [54] Soucek, K., Pachernik, J., Kubala, L., Vondracek, J., Hofmanova, J., and Kozubik, A. (2006) Transforming growth factor-beta1 inhibits all-trans retinoic acid-induced apoptosis, *Leuk Res* 30, 607-623.
  - [55] Tabe, Y., Shi, Y. X., Zeng, Z., Jin, L., Shikami, M., Hatanaka, Y., Miida, T., Hsu, F. J., Andreeff, M., and Konopleva, M. (2013) TGF-beta-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment, *PLoS One 8*, e62785.
- [56] Akhurst, R. J., and Hata, A. (2012) Targeting the TGFbeta signalling pathway in disease, *Nat Rev Drug Discov 11*, 790-811.
- [57] Yingling, J. M., Blanchard, K. L., and Sawyer, J. S. (2004) Development of TGF-beta signalling inhibitors for cancer therapy, *Nat Rev Drug Discov 3*, 1011-1022.
- [58] Hu, Y., and Smyth, G. K. (2009) ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays, *J Immunol Methods 347*, 70-78.
- 735 70-78.
  736 [59] Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A.,
  737 Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., and Mesirov, J. P. (2005)
  738 Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide
  739 expression profiles, *Proc Natl Acad Sci U S A 102*, 15545-15550.




Figure 1. Lower *TGIF1* expression was associated with adverse and higher *TGIF1* expression associated with favorable clinical outcome in AML. A, OS in patients (n = 20) with higher expression relative to reference is shown in top curve. Median survival in this group was not reached at last follow-up, with 70% of this group still alive. The survival of patients (n = 39) with lower expression is shown in bottom curve. Median survival in this group was 181 days (CI = 112-249 days), with 7.6% still alive. B, RFS in patients (n = 20) with TGIF1 expression greater than reference is shown in top curve. The survival of patients (n = 39) with lower TGIF1 expression is shown in bottom curve.






Figure 2. Analysis of OS in patients as a function of TGIF1 mRNA expression. A, Box-and-whiskers plot of OS expressed as days alive vs. ratio of TGIF1 expression in leukemia cells to commercial reference. Cases were subdivided into 4 groups according to TGIF1 expression ratios as shown. B, TGIF1 expression determined in 285 AML patients with Affymetrix U133A GeneChips (probe set 203313\_s\_at) and cases subdivided according to TGIF1 expression into 5 groups: < 50 (n = 20), 51-100 (n = 45), 101-150 (n = 107), 151-200 (n = 95), and > 200 (n = 18). Log-rank analysis was carried out using Microsoft Excel software.



**Figure 3.** MLL-AF9-induced AML in  $Tgif1^{-/-}$  mice was more aggressive than in  $Tgif1^{+/+}$  mice. Lin<sup>-</sup> bone marrow cells from  $Tgif1^{+/+}$  or  $Tgif1^{-/-}$  mice were transduced with MLL-AF9-GFP retrovirus and transduced cells transplanted into sub-lethally irradiated  $Tgif1^{+/+}$  and  $Tgif1^{-/-}$  recipient mice, respectively. Six weeks post-transplant, the percentages of **A**, GFP<sup>+</sup> cells; **B**, myeloid cells (CD11b<sup>+</sup> and Gr-1<sup>+</sup>) and **C**, B-lymphocytes (B220<sup>+</sup>) in peripheral blood (PB) were analyzed by flow cytometry.



**Figure 4.** *Tgif1* loss was associated with shorter survival *in vivo*. Kaplan-Meier survival curves for mice with the indicated genotype and MLL-AF9-induced AML. Lin<sup>-</sup> bone marrow cells from  $Tgif1^{+/+}$  and  $Tgif1^{-/-}$  mice were transduced with MLL-AF9-GFP retrovirus and transduced cells transplanted into sub-lethally irradiated  $Tgif1^{+/+}$  and  $Tgif1^{-/-}$  recipients, respectively.




Figure 5. LSC frequency was increased in  $Tgif1^{-/-}$  mice with AML compared to  $Tgif1^{+/+}$  mice. Lin-bone marrow cells from  $Tgif1^{+/+}$  and  $Tgif1^{-/-}$  mice were transduced with MLL-AF9-GFP retrovirus and transduced cells transplanted into sub-lethally irradiated  $Tgif1^{+/+}$  and  $Tgif1^{-/-}$  recipients, respectively. At a predetermined time, serial dilutions of spleen cells from mice with leukemia then collected and transplanted into secondary recipients. Kaplan-Meier analysis of survival is plotted as a function of number of transplanted spleen cells. **A**,  $1x10^6$ ; **B**,  $1x10^5$ ; **C**,  $1x10^4$ ; **D**,  $1x10^3$ .




Figure 6. AML in  $Tgif1^{-/-}$  mice progressed earlier after chemotherapy than in  $Tgif1^{+/+}$  AML mice. Sub-lethally irradiated C57BL/6 mice were transplanted with spleen cells from  $Tgif1^{+/+}$  or  $Tgif1^{-/-}$  mice with established MLL-AF9-induced AML, and two weeks following transplant, recipient mice were treated with doxorubicin for 3 days and cytarabine for 5 days by intraperitoneal injection. **A**, Percentage of GFP+ cells in peripheral blood two weeks post chemotherapy. **B**, Kaplan-Meier analysis of survival of  $Tgif1^{+/+}$  and  $Tgif1^{-/-}$  mice with AML after chemotherapy.




Figure 7. *Tgif1*<sup>-/-</sup> mice with BCR-ABL-induced CML had inferior survival compared to *Tgif1*<sup>+/+</sup> mice with CML. Lin<sup>-</sup> c-Kit<sup>+</sup> bone marrow cells from *Tgif1*<sup>+/+</sup> or *Tgif1*<sup>-/-</sup> mice were transduced with BCR-ABL-GFP retrovirus and transduced cells transplanted into C57BL/ 6J recipient mice. Recipient mice were **A**, lethally irradiated; **B**, sub-lethally irradiated.





Figure 8. Upstream regulator analysis of differentially expressed genes. This analysis identified TGF-b as a major regulator of differentially expressed genes ( $p=8.52 \times 10^{-10}$ ).

Table 1. Differentially expressed genes in  $TGIF1^{-/-}$  vs.  $TGIF1^{+/+}$  leukemic cells

ID	Symbol	Location	Log Ratio
Slc15a2	SLC15A2	Plasma Membrane	-7.651
Eps8l1	EPS8L1	Cytoplasm -7.587	
Dlgap1	DLGAP1	Plasma Membrane	-3.719
Gdf3	GDF3	Extracellular Space	-3.658
Camk2b	CAMK2B	Cytoplasm	-3.619
Col19a1	COL19A1	Extracellular Space	-3.488
Kenq5	KCNQ5	Plasma Membrane	-2.727
Vill	VILL	Cytoplasm	-2.499
Cgnl1	CGNL1	Plasma Membrane	-1.938
Cdkn2c	CDKN2C	Nucleus	-1.649
Gm15448	LILRB3	Plasma Membrane	-1.362
Selm	SELM	Cytoplasm	-0.761
Ly75	LY75	Plasma Membrane	0.652
Anxa3	ANXA3	Cytoplasm	0.714
Agap1	AGAP1	Cytoplasm	0.742
Ttc21a	TTC21A	Extracellular Space	0.967
Pip5k1b	PIP5K1B	Cytoplasm	0.976
B4galt6	B4GALT6	Cytoplasm	1.029
Ptgs1	PTGS1	Cytoplasm	1.045
Olfm4	OLFM4	Extracellular Space	1.123
Dsp	DSP	Plasma Membrane	1.212
Gfi1	GFI1	Nucleus	1.278
Plekha6	Plekha6	Other	1.291
Sept5	SEPT5	Cytoplasm	1.301
Optn	OPTN	Cytoplasm	1.325
Kenh7	KCNH7	Plasma Membrane	1.417
Fenb	FCN1	Extracellular Space 1.427	
S100a8	S100A8	Cytoplasm 1.503	
Gca	GCA	Cytoplasm 1.575	
Serpine2	SERPINE2	Extracellular Space 1.875	
Camp	CAMP	Cytoplasm	1.940
Serpine1	SERPINE1	Extracellular Space	2.160
Retnlg	Retnlg	Extracellular Space	2.167
Cd74	CD74	Plasma Membrane	2.609
C1qb	C1QB	Extracellular Space	3.161
C1qc	C1QC	Extracellular Space	3.269
Adam12	ADAM12	Plasma Membrane	3.167
C1qa	C1QA	Extracellular Space	3.503
Mmp14	MMP14	Extracellular Space	4.032
Thbs4	THBS4	Extracellular Space	4.578
Bmp1	BMP1	Extracellular Space	4.577
Npr1	NPR1	Plasma Membrane	5.607
Mtus2	MTUS2	Other	5.713
Syce1	SYCE1	Nucleus	7.905
4930447C04Rik	C14orf39	Extracellular Space	8.430

## **Supplemental Table S1. Patient characteristics.**


Characteristic	Number	Percentage
Total number	60	
Median age	48 (range 3-79)	
Age 3-17	6	10%
Age 18-45	21	35%
Age 46-60	19	32%
Age 60-79	14	23%
Males	28	47%
Females	32	53%
Newly diagnosed	53	88%
Relapsed	7	12%
Prior MDS	21	35%
Cytogenetics		
Good prognosis	6	10%
Intermediate prognosis	27	45%
Poor prognosis	22	37%
Induction therapy	49/53 newly diagnosed	92%
Salvage therapy	3/7 relapsed	43%
Achieved CR	35	58%
No response or PR	17	28%
Remission not evaluated	8	13%
SCT in CR1 or CR2	20	33%
Patients surviving	17	25%




**Supplemental Figure S1. Kaplan-Meier analysis of OS as function of** *TGIF1* **expression: TCGA AML dataset.** Kaplan-Meier analysis of OS for adult patients with AML from TCGA dataset, with *TGIF1* expression above the median (red continuous lines) or below the median (blue dotted lines) plotted for probe set 203313\_s\_at (*left*) and 1566901\_at (*right*).

# Supplemental Table S2. TGIF1 sequence variants in myeloblasts.


Polymorphism	TGIF region	Previously reported	Number
-33C>A	5' untranslated	Yes	9/49
-9G>A	5' untranslated	No	1/49
127C>G (P43A)	Coding	No	1/49
420A>G (P140P)	Smad2-interacting	Yes	7/49
487C>T (P163S)	Smad2-interacting	Yes	7/49
488C>T (P163L)	Smad2-interacting	Yes	7/49
713C>A (P238H)	Phosphorylation site	No	1/49
723G>A (P241P)	Phosphorylation site	No	1/49
744T>A (S248R)	mSin3A-interacting	No	1/49




Supplemental Figure S2. Quantitative RT-PCR analysis of *TGIF1* mRNA in leukemic blasts. Bar graph shows, in ascending order, mean *TGIF1* mRNA level ± SEM in myeloblasts from 43 patients with AML determined by real-time PCR analysis. *TGIF1* expression in human AML cell lines TF-1 and AML-193 are shown for comparison. The level of expression in the TF-1 cell line was assigned a value of 1 and all other measurements normalized to it.



Supplemental Figure S3. Quantitative RT-PCR analysis of TGIF1 mRNA in immortalized lymphoblasts. Bar graph shows mean TGIF1 mRNA level  $\pm$  SEM in ascending order in immortalized lymphoblast lines derived from 100 normal individuals.




**Supplemental Figure S4.** *Tgif1*<sup>-/-</sup> mice with CML have more aggressive disease than in *Tgif1*<sup>+/+</sup> mice. Enriched Lin<sup>-</sup> c-Kit<sup>+</sup> cells from *Tgif1*<sup>-/-</sup> bone marrow cells were transduced with BCR-ABL-GFP retrovirus and transduced cells transplanted into lethally irradiated C57BL/6J recipients to induce CML. Six weeks post-transplant, flow cytometry was used to analyze **A**, percentage of GFP<sup>+</sup> cells in PB; **B**, percentage of GFP<sup>+</sup> cells in bone marrow; **C**, number of GFP<sup>+</sup> LSK cells (or LSCs) in bone marrow.



Supplemental Figure S5. Kaplan-Meier analysis of survival in BCR-ABL-induced CML in mice as a function of Tgifl expression level. Enriched Lin<sup>-</sup> c-Kit<sup>+</sup> cells from  $Tgifl^{+/+}$  or  $Tgifl^{+/-}$  bone marrow cells were transduced with BCR-ABL-GFP retrovirus and transduced cells transplanted into sub-lethally irradiated C57BL/6J recipients to induce CML.





**Supplemental Figure S6. Canonical Pathway Analysis.** Depicted are differentially utilized pathways in leukemia cells from  $Tgifl^{-/-}$  compared to  $Tgifl^{-/-}$  mice.